Literature DB >> 19893496

Sexual dimorphism in the blood pressure response to angiotensin II in mice after angiotensin-converting enzyme blockade.

Marcia Venegas-Pont1, Julio C Sartori-Valinotti, Porter H Glover, Jane F Reckelhoff, Michael J Ryan.   

Abstract

BACKGROUND: The incidence of hypertension and progression of renal disease are greater in men than in women. Data suggest that there is a dimorphic response to angiotensin II (Ang II) in rats, with male rats exhibiting a greater increase in mean arterial pressure (MAP) than females. However, during endogenous renin-angiotensin system (RAS) blockade with angiotensin-converting enzyme (ACE) inhibition, female rats have a greater MAP response to Ang II. We tested whether female mice exhibit a greater MAP response to chronic Ang II during ACE inhibition.
METHODS: Twenty-week-old male and female C57BL/6J mice (n > or = 6/group), treated with enalapril (40 mg/kg/day in drinking water), were assigned to groups receiving either Ang II (800 ng/kg/min) or saline for 2 weeks. Enalapril treatment began 4 days before and continued throughout the experiment.
RESULTS: MAP was higher in male mice than female mice treated with enalapril and Ang II (male: 144 +/- 3 vs. female: 121 +/- 6 mm Hg, P < 0.05) and was not different between mice treated with enalapril alone (male: 99 +/- 3 vs. female: 100 +/- 3 mm Hg). F2-isoprostanes were not increased by Ang II; however, female mice had significantly higher levels than males. Renal cortical expression of catalase and Cu/Zn-superoxide dismutase (SOD) was not different between experimental groups. Urinary protein was higher in male mice when compared to females, but was not changed after treatment with Ang II in either group.
CONCLUSIONS: These data suggest that there are species and sex-specific differences in the mechanism of the blood pressure response to Ang II, even during ACE inhibition.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19893496      PMCID: PMC2829249          DOI: 10.1038/ajh.2009.203

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  21 in total

Review 1.  Gender differences in the regulation of blood pressure.

Authors:  J F Reckelhoff
Journal:  Hypertension       Date:  2001-05       Impact factor: 10.190

2.  Gender differences in development of hypertension in spontaneously hypertensive rats: role of the renin-angiotensin system.

Authors:  J F Reckelhoff; H Zhang; K Srivastava
Journal:  Hypertension       Date:  2000-01       Impact factor: 10.190

3.  Serum angiotensin-converting enzyme in healthy and sarcoidotic children: comparison with the reference interval for adults.

Authors:  B Bénéteau-Burnat; B Baudin; G Morgant; F C Baumann; J Giboudeau
Journal:  Clin Chem       Date:  1990-02       Impact factor: 8.327

4.  Gender differences in angiotensin-converting enzyme (ACE) activity and inhibition by enalaprilat in healthy volunteers.

Authors:  Pedro Zapater; Jesús Novalbos; Sonia Gallego-Sandín; Flavia T Hernández; Francisco Abad-Santos
Journal:  J Cardiovasc Pharmacol       Date:  2004-05       Impact factor: 3.105

5.  Species and strain differences in urinary protein excretion.

Authors:  J M Alt; B Maess; H Hackbarth
Journal:  Ren Physiol       Date:  1985

6.  Renin-angiotensin system blockade is renoprotective in immune complex-mediated glomerulonephritis.

Authors:  Shunhua Guo; Jolanta Kowalewska; Tomasz A Wietecha; Masayuki Iyoda; Li Wang; Kenneth Yi; Min Spencer; Miriam Banas; Sanda Alexandrescu; Kelly L Hudkins; Charles E Alpers
Journal:  J Am Soc Nephrol       Date:  2008-03-12       Impact factor: 10.121

7.  Role of inflammation in the development of renal damage and dysfunction in angiotensin II-induced hypertension.

Authors:  Tang-Dong Liao; Xiao-Ping Yang; Yun-He Liu; Edward G Shesely; Maria A Cavasin; William A Kuziel; Patrick J Pagano; Oscar A Carretero
Journal:  Hypertension       Date:  2008-06-09       Impact factor: 10.190

Review 8.  Sex differences in oxidative stress and the impact on blood pressure control and cardiovascular disease.

Authors:  Julio C Sartori-Valinotti; Radu Iliescu; Lourdes A Fortepiani; Licy L Yanes; Jane F Reckelhoff
Journal:  Clin Exp Pharmacol Physiol       Date:  2007-09       Impact factor: 2.557

9.  Sex and sex hormones influence the development of albuminuria and renal macrophage infiltration in spontaneously hypertensive rats.

Authors:  Jennifer C Sullivan; Laura Semprun-Prieto; Erika I Boesen; David M Pollock; Jennifer S Pollock
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2007-08-15       Impact factor: 3.619

10.  Rosiglitazone decreases blood pressure and renal injury in a female mouse model of systemic lupus erythematosus.

Authors:  Marcia Venegas-Pont; Julio C Sartori-Valinotti; Christine Maric; Lorraine C Racusen; Porter H Glover; Gerald R McLemore; Allison V Jones; Jane F Reckelhoff; Michael J Ryan
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-02-04       Impact factor: 3.619

View more
  13 in total

1.  Female C57BL/6J mice lacking the circadian clock protein PER1 are protected from nondipping hypertension.

Authors:  Lauren G Douma; Kristen Solocinski; Meaghan R Holzworth; G Ryan Crislip; Sarah H Masten; Amber H Miller; Kit-Yan Cheng; I Jeanette Lynch; Brian D Cain; Charles S Wingo; Michelle L Gumz
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2018-11-14       Impact factor: 3.619

2.  Sex differences in acute ANG II-mediated hemodynamic responses in mice.

Authors:  Markus P Schneider; Paul F Wach; Melissa K Durley; Jennifer S Pollock; David M Pollock
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2010-06-23       Impact factor: 3.619

3.  Oxidative stress contributes to sex differences in angiotensin II-mediated hypertension in spontaneously hypertensive rats.

Authors:  Kanchan Bhatia; Ahmed A Elmarakby; Azza B El-Remessy; Azza El-Remessey; Jennifer C Sullivan
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-11-02       Impact factor: 3.619

Review 4.  Sex and gender differences in control of blood pressure.

Authors:  Rodrigo Maranon; Jane F Reckelhoff
Journal:  Clin Sci (Lond)       Date:  2013-10       Impact factor: 6.124

5.  Tumor necrosis factor-alpha antagonist etanercept decreases blood pressure and protects the kidney in a mouse model of systemic lupus erythematosus.

Authors:  Marcia Venegas-Pont; Michaele B Manigrasso; Samira C Grifoni; Babbette B LaMarca; Christine Maric; Lorraine C Racusen; Porter H Glover; Allison V Jones; Heather A Drummond; Michael J Ryan
Journal:  Hypertension       Date:  2010-08-09       Impact factor: 10.190

6.  Angiotensin (1-7) receptor antagonism equalizes angiotensin II-induced hypertension in male and female spontaneously hypertensive rats.

Authors:  Jennifer C Sullivan; Kanchan Bhatia; Tatsuo Yamamoto; Ahmed A Elmarakby
Journal:  Hypertension       Date:  2010-08-16       Impact factor: 10.190

7.  Subfornical organ insulin receptors tonically modulate cardiovascular and metabolic function.

Authors:  Jin Kwon Jeong; Julie A Horwath; Hayk Simonyan; Katherine A Blackmore; Scott D Butler; Colin N Young
Journal:  Physiol Genomics       Date:  2019-06-07       Impact factor: 4.297

8.  Endothelin ET(B) receptors contribute to sex differences in blood pressure elevation in angiotensin II hypertensive rats on a high-salt diet.

Authors:  Wararat Kittikulsuth; Stephen W Looney; David M Pollock
Journal:  Clin Exp Pharmacol Physiol       Date:  2013-06       Impact factor: 2.557

9.  Sex-specific effects of heme oxygenase-2 deficiency on renovascular hypertension.

Authors:  Jacob M Stout; Monette U Gousset; Heather A Drummond; Will Gray; Brandon E Pruett; David E Stec
Journal:  J Am Soc Hypertens       Date:  2013-05-27

10.  Sex differences in angiotensin II-induced hypertension and kidney injury: role of AT1a receptors in the proximal tubule of the kidney.

Authors:  Ana Paula Oliveira Leite; Xiao C Li; Rumana Hassan; Xiaowen Zheng; Barbara Alexander; Dulce Elena Casarini; Jia L Zhuo
Journal:  Clin Sci (Lond)       Date:  2021-08-13       Impact factor: 6.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.